complex
compos
three
protein
protect
antigen
pa
lethal
factor
lf
oedema
factor
ef
complex
compos
vamp
also
refer
synaptobrevin
syntaxin
involv
membran
fusion
exocytosi
acetylcholin
neuromuscular
junction
lf
recogn
one
main
virul
compon
b
anthraci
consequ
much
interest
identifi
inhibitor
metalloproteas
sever
hydroxam
inhibitor
lf
identifi
one
k
nm
vitro
incorpor
metalchel
moieti
potent
inhibitor
mkarrkkvypnhoh
k
gener
use
inform
addit
peptid
inhibitor
identifi
tabl
panchal
et
al
use
highthroughput
assay
analys
nation
cancer
institut
nci
divers
set
sever
small
nonpeptid
molecul
druglik
properti
identifi
tabl
fig
compound
identifi
via
subsequ
threedimension
databas
mine
basi
compound
identifi
studi
common
pharmacophor
lf
inhibit
gener
provid
templat
identifi
new
lead
search
lf
inhibitor
also
prompt
applic
less
convent
technolog
exampl
mass
spectrometrybas
techniqu
use
identifi
inhibitor
tabl
final
natur
proven
pharmaceut
treasur
chest
natur
product
includ
ic
nm
isol
green
tea
tabl
aminoglycosid
includ
neomycin
b
k
nm
potent
lf
inhibitor
two
notabl
inhibitor
adenyl
cyclas
activ
ef
identifi
screen
avail
chemic
directori
databas
tabl
wherea
activ
metabolit
adefovir
dipivoxil
tabl
found
select
inhibit
ef
high
affin
botulinum
neurotoxin
botulinum
neurotoxin
bont
potent
biolog
toxin
tabl
easili
produc
deliv
via
aerosol
rout
seven
bont
serotyp
ag
cleav
specif
compon
solubl
nethylmaleimidesensit
factor
attach
protein
receptor
snare
complex
cleavag
impair
releas
acetylcholin
lead
deadli
flaccid
paralysi
toxin
compos
heavi
chain
promis
anoth
method
would
involv
interf
palf
paef
bind
event
polyval
compound
consist
polyacrylamid
backbon
substitut
multipl
copi
peptid
htstywwldgap
provid
protect
lf
final
identifi
gener
molecul
bind
within
pa
heptam
pore
therebi
block
lfef
releas
hostcel
cytosol
also
potenti
avenu
toxin
inhibit
anticip
research
nguyen
gener
structur
viabl
pa
heptam
model
use
futur
drug
discoveri
bind
hostcel
receptor
cleav
furinrel
proteas
give
activ
pa
c
pa
heptamer
bind
either
lethal
factor
lf
oedema
factor
ef
depict
heptam
bind
lf
complex
endocytos
lf
shown
ef
shown
transloc
endosom
hostcel
cytosol
e
therapeut
exampl
nsc
ref
design
enter
intox
cell
inhibit
proteas
activ
lf
f
surfac
depict
nsc
bound
within
lf
substratebind
cleft
shown
inhibitor
carbon
green
nitrogen
blue
oxygen
red
surfac
lf
red
acid
surfac
blue
basic
surfac
white
neutral
surfac
botulinum
human
human
antibodi
seven
serotyp
need
neurotoxin
murin
use
combin
affin
might
crucial
protect
broad
neutral
antibodi
need
antibodi
carboxyl
end
toxin
explor
site
avian
murin
shown
protect
vivo
critic
need
high
affin
antibodi
genet
inactiv
ricin
use
antigen
aerosol
ricin
induc
lung
damag
even
surviv
subject
adjunct
therapeut
desir
shown
protect
aerosol
toxin
enterotoxin
murin
need
antibodi
broad
neutral
activ
staphylococc
enterotoxin
molecular
dock
use
lc
obtain
avail
xray
crystal
structur
pharmacophor
bonta
lc
inhibit
gener
valu
ongo
drug
discoveri
furthermor
breidenbach
brunger
recent
solv
xray
cocryst
structur
bonta
lc
complex
residu
synaptosomalassoci
protein
import
structur
reveal
substraterecognit
exosit
could
exploit
inhibitor
design
toosendanin
triterpenoid
natur
product
might
act
exosit
major
compound
inhibit
bontb
metalloproteas
activ
pseudopeptid
natur
howev
two
nonpeptid
inhibitor
describ
tabl
regard
pseudopeptid
phosphoramidon
three
synthet
deriv
found
weak
inhibitor
wherea
buforin
also
shown
activ
bontb
lc
recent
cyscontain
peptid
inhibitor
also
report
effect
pseudopeptid
bontb
lc
inhibitor
date
identifi
cours
sever
complementari
studi
initi
seri
pseudotripeptid
nomin
k
valu
gener
subsequ
public
sidechain
modif
produc
potent
inhibitor
tabl
latest
studi
pseudotripeptid
inhibitor
subject
minor
structur
chang
sever
compound
k
valu
rang
nm
nm
gener
symmetr
disulphid
deriv
display
greatest
potenc
tabl
regard
bont
serotyp
f
lc
schmidt
stafford
recent
gener
potent
peptid
inhibitor
compos
vamp
residu
j
j
schmidt
r
g
stafford
person
commun
potenc
ricin
toxin
show
tabl
prepar
inhibitor
develop
monzingo
robertu
solv
cocryst
structur
two
substrat
analogu
formycin
monophosph
fmp
dinucleotid
apg
bound
ricin
toxin
chain
rta
use
fmprta
cocryst
guid
yan
et
al
identifi
pterinbas
inhibitor
pteroic
acid
neopterin
tabl
inhibitor
cocrystal
rta
fig
followup
studi
oxazolepyrimidin
ring
system
tabl
also
found
inhibit
rta
aptam
nucleicacid
ligand
inhibit
rta
also
gener
hesselberth
et
al
identifi
aptam
wherea
tanaka
et
al
use
mechanist
approach
gener
varieti
much
smaller
aptam
contain
unnatur
sugar
purin
deriv
tabl
staphylococc
enterotoxin
staphylococc
enterotoxin
se
stimul
power
cytokin
immun
respons
earn
name
superantigen
sag
figur
show
cocryst
sag
human
class
ii
major
histocompat
complex
mhc
molecul
se
relat
exotoxin
implic
variou
disord
hc
target
gangliosid
receptor
nerv
termin
form
lowph
endosom
transloc
light
chain
lc
nerv
cytosol
lc
act
zinc
metalloproteas
respons
snare
protein
cleavag
hc
lc
therefor
provid
two
viabl
target
neutral
toxin
vast
major
research
identifi
bont
therapeut
focus
serotyp
b
regard
inhibit
hc
activ
deshpand
et
al
sheridan
et
al
propos
sever
antimalari
compound
delay
muscl
paralysi
follow
bont
serotyp
bonta
challeng
act
interf
acid
toxinmedi
endosom
addit
eswaramoorthi
et
al
gener
cocryst
structur
doxorubicin
bound
within
bont
serotyp
b
bontb
hc
gangliosidebind
site
inhibitor
would
interfer
abil
toxin
bind
neuron
receptor
lc
inhibitor
would
crucial
rescu
nerv
activ
toxin
intern
search
therapeut
number
short
hing
peptid
inhibitor
bonta
lc
describ
howev
structur
hing
peptid
deconvolut
test
mixtur
use
substratetoinhibitor
strategi
schmidt
cowork
gener
potent
inhibitor
bonta
lc
tabl
subsequ
similar
strategi
use
sukonpan
et
al
identifi
addit
peptid
inhibitor
recent
studi
small
nonpeptid
nonchel
druglik
molecul
inhibit
bonta
lc
discov
tabl
two
potent
inhibitor
michellamin
b
fig
shown
although
consensu
peptid
therapeut
present
controversi
anim
model
mimet
peptid
shown
diminish
toxic
sag
one
studi
arad
colleagu
use
mimet
peptid
produc
evid
diverg
sag
inhibit
gene
express
human
h
cytokin
low
molar
excess
sag
challeng
concentr
peptid
mimet
protect
mice
lethal
effect
broad
spectrum
toxin
even
given
postchalleng
peptid
mimet
domain
structur
conserv
among
sag
yet
remot
bind
site
mhc
class
ii
tcr
propos
sag
might
use
domain
bind
novel
receptor
crucial
action
kaempfer
r
person
commun
lethal
shock
syndrom
mani
exotoxin
rel
easi
produc
larg
quantiti
remark
stabl
deliv
aerosol
agent
highli
incapacit
lethal
modul
cytokin
respons
one
clear
mechan
interfer
se
toxic
solubl
decoy
receptor
highaffin
variant
tcell
receptor
tcr
region
engin
counteract
se
therapeut
lead
addit
studi
gener
protein
sever
toxin
picomolar
affin
r
buonpan
kranz
person
commun
high
affin
might
essenti
neutral
agent
sag
highli
toxic
even
extrem
low
concentr
cytomegaloviru
cmv
therapi
prophylaxi
influenza
viru
howev
caus
optim
virus
greatest
concern
biowarfar
bioterror
caus
acut
viral
infect
lucki
survivor
follow
immun
recoveri
antivir
therapi
therefor
need
effect
rel
short
period
see
box
case
exampl
filovirus
orthopoxvirus
attach
entri
remain
enigma
filovirus
orthopoxvirus
emerg
data
mire
uncertainti
controversi
search
specif
filoviru
receptor
counter
evid
ubiquit
unspecif
lectinlik
receptor
fusion
inhibit
proven
fruit
treat
hiv
influenza
could
provid
therapeut
opportun
viral
genera
activ
pursu
inhibit
viral
replic
seem
especi
feasibl
filovirus
orthopoxvirus
numer
genom
sequenc
sever
key
enzym
identifi
basic
replic
step
describ
structur
associ
among
protein
partial
describ
abund
potenti
target
could
result
sever
therapeut
approach
includ
antisens
target
viral
genom
inhibit
replicas
polymeras
activ
smallmolecul
inhibitor
well
specif
molecular
target
essenti
format
replicationcompet
complex
recent
develop
revers
genet
filoviru
reporterbas
minigenom
well
green
fluoresc
protein
gfp
express
ebola
viru
expect
significantli
facilit
identif
inhibitor
filoviru
replic
final
assembl
viral
egress
cell
simpler
filovirus
poxvirus
result
electron
microscopi
long
indic
final
assembl
filament
ebola
marburg
virus
occur
cell
membran
recent
work
shown
filovirus
among
subset
virus
exploit
special
cellmembran
region
call
lipid
raft
filoviru
raft
assembl
might
therefor
viabl
target
revers
genet
experi
use
explor
whether
put
target
furin
cleavag
site
ebola
viru
essenti
viral
infect
compar
filovirus
poxviru
egress
cell
consider
complic
situat
would
seem
make
target
even
vulner
year
vaccinia
viru
mutant
defect
variou
aspect
final
assembl
identifi
host
protein
implic
therapeut
viral
infect
broadli
categor
agent
attack
viru
replic
cycl
directli
agent
assist
fortifi
host
immun
defenc
principl
abund
target
numer
strategi
categori
tabl
provid
overview
strategi
opportun
avail
new
therapi
viru
juxtapos
challeng
bring
strategi
clinic
use
view
present
necessarili
incomplet
serv
highlight
appar
vulner
virus
extraordinari
challeng
inher
dampen
logarithm
viral
replic
medic
signific
degre
review
recent
de
clercq
antibodi
viral
glycoprotein
conjunct
tcell
respons
protein
requir
optim
protect
attempt
influenc
clinic
outcom
human
transfer
plasma
convalesc
ill
individu
produc
encourag
result
studi
inadequ
control
therefor
inconclus
common
observ
orthopoxvirus
product
neutral
antibodi
rais
inactiv
viru
alon
prove
insuffici
prevent
diseas
death
protect
combin
addit
antibodi
popul
found
serum
anim
infect
live
viru
repeat
observ
monoclon
antibodi
dna
vaccin
evok
antibodi
case
even
potent
neutral
antibodi
vaccinia
viru
protein
insuffici
prevent
inexor
spread
viru
infect
anim
contrast
antibodi
viral
encod
cellsurfac
protein
suffici
conjunct
provid
robust
protect
vaccinia
viru
rodent
other
extend
observ
addit
protein
report
similar
find
experiment
dna
vaccin
monkeypox
viru
nonhuman
primat
yield
concord
result
rais
question
might
antibodi
addit
neutral
antibodi
confer
therapeut
effect
earli
observ
implic
capac
antibodi
bind
viral
protein
surfac
infect
cell
subsequ
observ
includ
filovirus
orthopoxvirus
tend
consist
propos
requir
target
nonneutr
antibodi
extern
expos
mechanist
one
might
evok
complementmedi
lysi
cell
antibodydepend
cellular
cytotox
fc
receptorbear
cell
destroy
viral
infect
cell
perturb
late
event
viral
assembl
drug
target
compound
identifi
inhibit
late
particl
format
addit
appar
effect
problemat
antivir
drug
cidofovir
seem
effect
mani
orthopoxvirus
potenti
use
treatment
smallpox
vaccinia
adjunct
therapi
filoviru
infect
associ
number
patholog
condit
includ
dissemin
intravascular
coagul
propos
result
upregul
tissu
factor
surfac
leukocyt
partial
success
ebola
viru
infect
rhesu
monkey
use
recombin
nematod
anticoagul
protein
recent
report
although
studi
encourag
util
anticoagul
therapi
human
requir
studi
particular
combin
specif
antivir
therapeut
therapeut
antibodi
filovirus
orthopoxvirus
illustr
potenti
complex
effect
antibodymedi
protect
often
underestim
viral
neutral
commonli
interpret
mean
capac
immunoglobulin
interfer
viral
attach
entri
part
protect
role
antibodi
sometim
insuffici
rodent
model
lethal
ebola
marburg
virus
administr
polyclon
monoclon
antibodi
unambigu
confer
protect
sometim
viral
infect
demonstr
virusneutr
activ
transfer
antibodi
poor
predictor
efficaci
vivo
antibodi
test
sensit
nonhuman
primat
model
filoviru
infect
delay
viraemia
death
fulli
prevent
viral
challeng
robust
led
prematur
assert
irrelev
antibodi
filoviru
therapi
lesson
viral
vaccin
studi
ebola
marburg
virus
repeatedli
show
recent
crucial
role
natur
killer
nk
cell
defin
protect
ebola
infect
interestingli
adopt
transfer
nk
cell
treat
ebola
viruslik
particl
inactiv
ebola
viru
result
signific
protect
mice
lethal
challeng
indic
mobil
effector
innat
respons
earli
infect
might
promis
therapeut
strategi
filovirus
target
host
pathway
viral
pathogen
evolv
millennia
adapt
limit
number
cellular
mechan
cellular
entri
replic
assembl
bud
although
tremend
amount
effort
devot
past
decad
develop
therapeut
strategi
target
viru
compon
half
work
involv
singl
viru
hiv
contrast
common
cellular
pathway
use
wide
array
virus
larg
neglect
therapeut
target
regard
genet
engin
microb
repres
major
challeng
biodef
pathogen
organ
might
unrecogn
andor
pathogen
might
tailor
counter
exist
pathogentarget
therapeut
hosttarget
therapeut
would
viabl
option
cope
unpredict
challeng
hosttarget
therapeut
would
two
advantag
would
act
broadspectrum
therapeut
block
virus
use
affect
pathway
would
make
difficult
pathogen
develop
resist
would
altern
cellular
pathway
avail
viru
take
advantag
besid
cellular
receptor
cofactor
number
intracellular
pathway
vacuolar
proteinsort
machineri
cytoskelet
network
compon
cellular
antivir
defenc
identifi
crucial
viral
pathogenesi
howev
despit
advanc
understand
host
pathway
involv
viral
pathogenesi
remain
limit
genet
approach
case
orthopoxvirus
target
particularli
import
quantit
minor
viral
popul
term
therapeut
valu
antibodi
complex
ad
search
antibodi
addit
assay
rapidli
bind
neutral
histor
potenc
vaccinia
immun
globulin
licens
treatment
smallpox
vaccin
complic
judg
neutral
capac
strategi
salvag
acquisit
antibodi
donor
whose
sera
also
contain
mani
antibodi
well
augment
protect
innat
immun
goal
antivir
agent
tip
balanc
immun
respons
toward
innat
immun
allow
specif
immun
clearanc
mechan
adapt
immun
take
crossroad
mani
innat
immun
respons
interferon
famili
molecul
directli
evok
antivir
respons
howev
util
interferon
broadspectrum
antivir
limit
transienc
toxic
effect
engend
caution
prospect
broad
array
newli
describ
cytokin
also
stimul
innat
immun
hand
opportun
drug
intervent
arisen
target
viral
pathogen
identif
protein
produc
vaccinia
influenza
viru
act
interferon
antagonist
follow
demonstr
ebola
marburg
virus
also
make
interferon
antagonist
addit
orthopoxvirus
synthes
impress
array
homologu
cytokin
cytokin
receptor
complement
protein
growth
hormon
molecul
effect
could
confound
innat
immun
respons
abil
modifi
innat
immun
respons
therapeut
signific
manner
necessit
deeper
understand
role
compon
arm
immun
system
specif
viral
infect
provid
tabl
choic
second
third
antibiot
influenc
like
resist
pattern
strain
caus
infect
consider
given
antibiot
penetr
bloodbrain
barrier
penicillin
carbapenem
exampl
due
high
frequenc
mening
associ
inhal
anthrax
exposur
durat
therapi
controversi
involv
least
day
treatment
corticosteroid
mention
possibl
adjunct
therapi
set
mening
sever
mediastin
oedema
data
definit
support
use
major
concern
regard
b
anthraci
microbi
biodef
agent
genet
engin
antibiot
resist
sever
report
recombin
rna
interfer
rnai
well
variou
physic
function
knockout
technolog
need
appli
identifi
host
genet
pathway
involv
viral
pathogenesi
establish
degre
common
pathway
across
viral
famili
molecular
detail
pathway
natur
interact
viral
compon
need
intens
studi
genet
biochem
structur
model
approach
detail
bodi
knowledg
would
serv
basi
identifi
host
target
ration
design
broadspectrum
therapeut
strategi
time
therapeut
protocol
treat
infect
mani
bacteri
biowarfar
pathogen
howev
scope
recoveri
variablein
case
individu
infect
inhal
anthrax
limit
window
opportun
antibiot
control
elimin
infect
section
review
cover
characterist
tabl
current
drug
therapi
three
biowarfar
agent
anthrax
plagu
tularaemia
natur
occur
strain
b
anthraci
gener
suscept
penicillin
firstgener
import
initi
combin
therapi
exposur
genet
modifi
strain
suspect
yersinia
pesti
typic
suscept
vitro
penicillin
mani
cephalosporin
imipenem
meropenem
aminoglycosid
amikacin
quinolon
tetracyclin
variabl
suscept
trimethoprim
chloramphenicol
rifampin
commonli
resist
macrolid
clindamycin
novobiocin
quinupristindalfopristin
clofazamin
h
hein
person
commun
see
tabl
recommend
antibiot
treatment
pneumon
plagu
prefer
therapi
pesti
infect
aminoglycosid
streptomycin
fdaapprov
medic
gentamicin
often
mention
altern
antibiot
although
rare
report
natur
occur
highli
antibioticresist
strain
pesti
occur
recent
report
strain
isol
boy
madagascar
demonstr
acquir
plasmid
mediat
resist
streptomycin
chloramphenicol
tetracyclin
also
ampicillin
sulphonamid
kanamycin
spectinomycin
minocyclin
natur
occur
highli
resist
antibiot
strain
extrem
concern
respect
develop
biolog
weapon
francesella
tularensi
gener
suscept
vitro
aminoglycosid
tetracyclin
rifampin
chloramphenicol
howev
mani
strain
seem
resist
monobactam
antibiot
see
tabl
recommend
tularaemia
treatment
similarli
treatment
plagu
streptomycin
gentamicin
prefer
therapi
contraind
use
medic
ciprofloxacin
effect
treat
recent
tularaemia
outbreak
spain
earli
detect
diagnosi
infect
intox
biolog
select
agent
toxin
bsat
essenti
intervent
occur
point
prognosi
still
influenc
also
guid
select
optimum
therapeut
protocol
tabl
addit
inform
greatli
facilit
logist
mobil
suppli
personnel
area
exposur
detect
defin
includ
technolog
requir
identifi
biolog
threat
environ
coincid
exposur
environment
detect
usual
involv
test
air
soil
fomit
water
foodstuff
laboratori
diagnosi
includ
method
use
confirm
clinic
observ
physician
evalu
standard
clinic
specimen
blood
serum
exud
saliva
stool
tissu
tabl
necess
rapid
detect
bsatrel
ill
intervent
optim
therapeut
protocol
well
illustr
anthrax
attack
box
network
nation
laboratori
respons
network
lrn
bioterror
establish
cdc
test
biolog
chemic
agent
see
fig
plasmid
confer
antibiot
resist
insert
b
anthraci
publish
one
plasmidcontain
strain
resist
tetracyclin
doxycyclin
minocyclin
anoth
studi
recombin
plasmid
encod
resist
penicillin
tetracyclin
chloramphenicol
rifampin
macrolid
lincomycin
insert
b
anthraci
strain
reportedli
stabli
inherit
plasmid
sever
gener
possibl
antibiot
resist
pathogen
indic
monkeypox
rodent
viru
endem
africa
far
less
contagi
variola
outbreak
caus
mortal
unvaccin
individu
classic
smallpox
vaccin
consist
vaccinia
viru
afford
rel
robust
protect
variola
monkeypox
virus
proven
problemat
modern
era
previous
known
advers
reaction
includ
dissemin
vaccinia
rediscov
associ
myocard
howev
safer
vaccin
research
pipelin
vaccinia
immun
globulin
antibodycontain
product
vaccin
person
licens
offer
investig
statu
treatment
dissemin
vaccinia
caus
agent
plagu
aerob
gramneg
bacillu
bacteri
famili
enterobacteriacea
system
wellestablish
microbiolog
method
pcr
gene
amplif
improv
immunodiagnost
assay
cdcsuppli
reagent
standard
exist
identif
b
anthraci
bonta
pesti
f
tularensi
brucella
spp
larg
number
agent
specimen
must
sent
directli
cdc
atlanta
georgia
usa
design
lrn
refer
laboratori
extrem
hazard
repres
clinic
laboratori
personnel
technic
complex
analysi
requir
case
lrn
system
requir
combin
screen
evalu
level
local
hospit
clinic
laboratori
confirm
hierarch
refer
laboratori
system
tabl
show
estim
time
requir
conduct
lrn
protocol
assum
lowcomplex
sampl
specimen
expect
time
requir
laboratori
confirm
wors
sampl
must
transport
schemat
process
could
use
terror
incid
laboratori
lrn
follow
rule
sampl
collect
ship
agent
contain
test
lrn
laboratori
maintain
secur
commun
channel
among
state
local
health
author
cdc
feder
agenc
mission
lrn
maintain
laboratori
network
quickli
respond
act
biolog
chemic
terror
system
organ
collect
surveil
previous
known
level
confirmatori
level
b
c
nation
laboratori
level
fdaapprov
assay
exist
bsat
cdc
therefor
provid
lrnregist
clinic
laboratori
frontlin
laboratori
respond
biolog
terror
approv
protocol
categori
agent
categori
b
agent
lrn
protocol
use
integr
caus
agent
tularaemia
small
aerob
gramneg
coccobacilli
agent
infecti
human
pathogen
known
past
former
soviet
union
us
programm
develop
weapon
contain
bacterium
complex
cycl
cell
defenc
cascad
amplifi
specif
binddisrupt
viral
proteinnucleicdeliveri
activ
compound
transcript
translat
viral
antagonist
intraand
acid
function
interact
exampl
intracellular
target
identif
genom
replic
extracellular
defenc
produc
proteas
inhibitor
replicas
inhibitor
appropri
target
escap
mutant
viral
protein
cell
surfac
competit
inhibit
viral
antagonist
innat
variat
among
viral
strain
express
viral
protein
adapt
immun
specif
target
viral
insuffici
knowledg
safe
secret
mhcassoci
viral
protein
cell
surfac
exampl
manipul
immun
system
peptid
process
perturb
antibodi
adcc
target
toxin
without
exacerb
diseas
normal
cell
surfac
exploit
amplifi
influenc
innat
autoimmun
individu
adapt
respons
exampl
nk
cell
ctl
elimin
modifi
self
specif
quasispecif
identifi
inhibit
proteinprotein
deliveri
activ
compound
orchestr
associ
viral
protein
interact
perturb
nucleicacid
intracellular
target
identif
compartment
nucleic
acid
encapsid
motif
exampl
use
appropri
target
encapsid
drug
antagonist
antisens
nucleic
acid
viral
protein
final
assembl
selfassembl
driven
specif
bind
disrupt
protein
involv
final
deliveri
activ
compound
involv
bind
movement
protein
packag
revers
perturb
essenti
intracellular
target
identif
transloc
preferenti
assembl
special
cellular
site
protein
appropri
target
overal
safeti
acquisit
outer
protein
exampl
lipid
raft
compound
disrupt
cellular
capsid
andor
bud
exploit
cellular
protein
process
cell
membran
pathway
exampl
cell
exhaust
apoptosi
death
repitit
vivo
logarithm
amplif
treat
symptom
sustain
victim
discoveri
activ
compound
manifest
viral
burden
fatal
virusinduc
immun
system
prevail
manag
address
issu
drug
antibodi
tissu
tropism
lesion
crucial
organ
trigger
immun
respons
cytokin
polar
pharmacokinet
bioavail
damag
diseas
cytokin
storm
efficaci
feasibl
safeti
immunopatholog
potent
lag
respons
state
publichealth
laboratori
use
lrn
protocol
assay
similar
surveil
system
plan
post
offic
research
begun
devis
system
protect
build
use
smart
monitor
system
presum
confirm
intent
releas
biolog
agent
local
offici
implement
respons
plan
might
includ
widespread
prophylaxi
treatment
accord
publichealth
threat
biosens
program
use
epidemiolog
method
monitor
select
surrog
marker
infecti
diseas
outbreak
emerg
room
visit
absente
rate
school
work
pharmaci
visit
indic
possibl
limit
biowatch
biosens
describ
box
tradit
immunodetect
detect
agentspecif
antibodi
tradit
method
confirm
clinic
diagnos
other
demonstr
assay
rapid
detect
anthraxspecif
antibodi
patient
sera
recent
fda
approv
use
first
commerci
assay
detect
anthraxspecif
antibodi
high
sensit
specif
although
assay
sensit
detect
anthraxspecif
antibodi
highli
immun
individu
convalesc
sera
might
effect
identifi
patient
earli
stage
diseas
among
postal
worker
arguabl
receiv
central
respond
cdc
laboratori
screen
local
level
requir
smallpox
haemorrhag
fever
basi
limit
public
report
respons
anthrax
attack
calcul
median
time
first
medic
visit
laboratori
confirm
suspect
cutan
inhal
anthrax
case
n
day
case
optim
antibiot
set
initi
first
therapeut
option
diagnosi
depend
astut
observ
sensit
attend
physician
possibl
anthrax
although
laboratori
respons
technic
improv
sinc
reaction
unknown
genet
engin
threat
could
mimic
experi
watch
sens
biothreat
agent
two
feder
sponsor
program
biowatch
biosens
earli
stage
implement
encourag
recognit
biolog
threat
attack
wide
scale
biowatch
program
collabor
program
environment
protect
agenc
epa
depart
homeland
secur
dh
cdc
local
author
provid
roundtheclock
environment
monitor
intent
airborn
releas
select
biolog
threat
solidphas
filter
sometim
aqueou
concentr
biowatch
air
sampler
evalu
presenc
pathogen
design
local
analysi
product
could
one
approach
approach
call
triangul
identif
genet
evalu
risk
tiger
provid
highthroughput
multipl
detect
identif
system
nearli
known
newli
emerg
bioengin
agent
singl
test
rapid
robust
culturefre
system
use
identifi
agent
sever
acut
respiratori
syndrom
sar
relat
coronaviru
recognit
tradit
method
robust
portabl
system
propos
develop
civilian
militari
applic
biosens
repres
anoth
evolv
mechan
earli
detect
singl
proteinac
nanometerscal
pore
anthrax
pa
easili
appli
provid
physic
basi
rapid
biosens
applic
mechan
nanoporebas
detect
simpl
analyt
either
bind
nanopor
thread
alter
ionic
current
characterist
manner
exampl
revers
bind
hydronium
deuterium
ion
ion
channel
caus
current
fluctuat
amplitud
spectral
signatur
indic
type
concentr
isotop
present
ion
channel
also
use
detect
character
individu
molecul
singlestrand
dna
driven
electrophoret
pore
latter
technolog
use
detect
analyt
solut
highest
dose
anthrax
spore
anthrax
attack
mean
durat
exposur
onset
diseas
day
diseas
onset
case
would
prior
develop
robust
humor
antibodi
respons
moreov
need
collect
pair
acut
convalesc
sera
could
limit
use
assay
epidemiolog
tool
promis
new
technolog
could
enabl
earli
recognit
replic
aetiolog
agent
virul
factor
potenti
amplif
variabl
gene
region
flank
conserv
sequenc
follow
electrospray
ioniz
mass
spectrometri
basecomposit
anthrax
attack
although
sever
patient
exposur
anthrax
spore
confirm
nasal
swab
cultur
case
diseas
occur
senat
staff
postal
worker
immedi
target
postexposur
chemoprophylaxi
contrast
postsyndrom
group
inhal
anthraxinfect
patient
case
mortal
rate
approxim
data
consist
studi
suggest
earli
aggress
treatment
necessari
influenc
surviv
exposur
inhal
anthrax
hostdirect
detect
power
approach
identifi
expos
infect
individu
develop
highli
specif
extrem
sensit
innat
biomark
detect
earli
exposur
biolog
agent
number
differ
type
biomark
one
effect
method
identifi
highli
specif
acut
sensit
biomark
use
geneand
proteinexpressionprofil
technolog
advantag
geneexpress
studi
largescal
abl
monitor
geneexpress
chang
across
entir
genom
one
assay
high
throughput
highli
cost
effect
rel
method
exampl
one
area
technolog
receiv
greatest
attent
identifi
biomark
cancer
field
express
profil
accept
power
tool
identifi
specif
biomark
diseas
progress
discrimin
differ
subtyp
cancer
case
identifi
biomark
suscept
specif
therapeut
regard
infecti
diseas
express
profil
human
neutrophil
expos
bacteria
reveal
dramat
chang
level
hundr
mrna
speci
includ
cytokin
receptor
membranetraffick
regul
gene
involv
apoptosi
importantli
express
profil
neutrophil
respons
indic
key
differ
mrnaexpress
pattern
could
detect
basi
whether
cell
expos
pathogen
nonpathogen
bacteria
studi
virushost
interact
use
express
technolog
genom
system
studi
hostpathogen
interact
identifi
specif
host
factor
pathogen
subvert
optim
replic
life
cycl
recent
geneexpressionprofil
technolog
appli
identif
biomark
predict
toxic
compound
field
toxicogenom
receiv
much
interest
commerci
academ
sector
capabl
success
predict
toxic
compound
drug
develop
research
well
environment
studi
exist
expertis
could
har
appli
develop
predict
model
assess
extent
exposur
biolog
agent
diseas
progress
predict
clinic
outcom
futur
creation
wide
avail
humangeneexpress
databas
respons
biolog
threat
agent
would
extrem
benefici
rapid
decis
identif
agent
via
quick
simpl
blood
test
tradit
method
identif
biolog
agent
focus
identifi
agent
rather
identifi
host
respons
howev
mani
biolog
agent
haemorrhag
fever
virus
could
infecti
level
well
limit
detect
afford
current
technolog
human
innat
immun
system
exquisit
refin
highli
sensit
highli
specif
detect
system
pathogen
monitor
chang
host
innat
respons
via
biomark
novel
method
identifi
exposur
biowarfar
agent
earli
time
point
specif
analyt
interest
bind
site
poreperm
polynucleotid
alter
abil
dna
enter
thread
pore
approach
extend
biosens
anthrax
toxin
pm
amount
j
kasianowicz
k
halverson
person
commun
although
biowatch
biosens
program
repres
signific
improv
biolog
defenc
readi
could
howev
fail
influenc
morbid
mortal
case
attack
biowatch
probabl
document
attack
biolog
threat
agent
use
scale
weapon
mass
destruct
howev
extens
epidemiolog
surveil
might
still
necessari
widescal
prophylaxi
implement
anoth
issu
yet
resolv
whether
environment
sampl
suffici
trigger
widescal
medic
respons
fda
might
review
environment
detect
technolog
influenc
medic
decisionmak
measur
conserv
approach
like
anthrax
attack
senat
worker
screen
success
treat
initi
environment
test
result
confirm
treatment
popul
might
delay
confus
lack
reliabl
laboratori
confirm
biowatch
sampler
might
effect
limit
attack
individu
contamin
water
food
sourc
case
biosens
surrog
marker
infecti
diseas
outbreak
lag
indic
attack
could
hundr
thousand
case
outbreak
recogn
depend
sensit
final
system
smallpox
viru
compar
long
incub
time
day
tabl
time
biosens
detect
smallpox
attack
multipl
foci
infect
across
countri
coincid
close
contact
spread
would
like
alreadi
develop
use
current
diseas
model
c
b
figur
schemat
compon
nation
laboratori
respons
network
lrn
coordin
detect
diagnos
biothreat
agent
initi
respond
collect
evid
sent
surveil
laboratori
confirmatori
laboratori
directli
b
c
cooper
laboratori
facilit
first
line
respons
procedur
confirm
agent
type
area
distribut
conduct
nation
laboratori
facilit
research
focus
complet
time
manner
addit
potenti
new
therapeut
emerg
drug
discoveri
pipelin
greater
involv
pharmaceut
industri
requir
accept
fact
industri
adept
translat
research
rapidli
effect
convert
potenti
therapi
approv
drug
howev
incent
need
put
place
encourag
pharmaceut
industri
conduct
costli
studi
unifi
biodef
entiti
major
facilit
role
present
project
bioshield
start
need
seriou
improv
abil
develop
new
therapeut
approv
drug
strateg
stockpil
urgent
howev
new
technolog
detect
releas
biothreat
agent
time
protocol
specif
diagnosi
biothreat
agent
use
need
turn
could
prevent
chao
experienc
anthrax
attack
start
make
plan
today
unifi
effort
possibl
creat
true
biodef
shield
effect
curtail
futur
act
bioterror
work
review
manuscript
provid
evid
scientif
commun
turn
blind
eye
counter
biothreat
agent
respond
massiv
effort
result
steep
product
learn
curv
effort
facilit
time
signific
increas
support
fund
agenc
howev
seriou
lack
organ
biodef
current
address
exist
prepared
respons
measur
suffici
meet
challeng
bioterrorist
attack
due
lack
cooper
coordin
also
ineffect
detect
network
lack
timeeffect
diagnost
methodolog
dearth
clear
vision
strategi
translat
publicli
fund
biodef
research
use
therapi
antidot
issu
easili
mitig
unifi
plan
action
orchestr
central
entiti
overse
comprehens
organ
approach
biodef
forese
central
entiti
play
pivot
role
ensur
crosscommun
agenc
